“Adjuvant” Chemotherapy
Sometimes chemotherapy is used following surgery when it is assumed that a metastatic cancer is left behind that the surgery could not remove. This is called adjuvant therapy. Tumours in which this approach is regularly used include osteosarcoma, haemangiosarcoma and feline injection site sarcoma. Under some circumstances this approach is also used in mammary, thyroid, anal sac, bladder and tonsillar cancers.
Palliative Chemotherapy
Chemotherapy can be used to enhance quality of life without there being a strong likelihood that the tumour would ever go into complete remission as a consequence of therapy. The quality of life improvements that are seen in this context can be marked. This approach to the management of veterinary cancer is used in particular in the management of inoperable mast cell tumours, anal sac tumours, bladder cancer, osteosarcoma (in conjunction with radiotherapy) and feline injection site sarcomas.
“Neoadjuvant” Chemotherapy
A relatively recent innovation in chemotherapy is the administration of treatment prior to definitive surgical intervention. It is supposed that this reduces the size and invasiveness of a primary tumour, increasing the surgical cure rate. This is called neoadjuvant therapy. In our clinic this approach is currently used primarily in the management of canine lung tumours and mast cell tumours and in feline injection site sarcomas.
Chemotherapy Safety
Chemotherapy is cytotoxic. This means that it can cause birth defects, genetic mutations and even cancer. For that reason appropriate precautions must be taken when handling chemotherapy and treatment should only be administered to appropriate patients. Chemotherapy metabolites are excreted in the urine and faeces and care must therefore be taken when handling body waste. All owners of patients receiving chemotherapy should be educated in matters relating to waste management.
Personnel involved in the purchase, storage, preparation and administration of chemotherapy must be adequately trained. Employers have a legal obligation to provide adequate training and safety equipment under the Control of Substances Hazardous to Health (CoSHH) Regulations 2002. Guidelines are available for safe handling of cytotoxic drugs under Appendix 1 of the CoSHH Approved Code of Practice.